Showing 2861-2870 of 6036 results for "".
- Study: Drinking Wine May Help Protect Against Cataractshttps://modernod.com/news/study-drinking-wine-may-help-protect-against-cataracts/2479033/People who consume alcohol moderately appear less likely to develop cataracts that require surgery. Wine consumption showed the strongest protective effect, suggesting that antioxidants which are abundant in red wine may play a role in cataract prevention. However, people who d
- UMass Medical School and AEYE Health Leverage AI to Help Family Doctors Screen and Refer Patients With Eye Conditions to Specialistshttps://modernod.com/news/umass-medical-school-and-aeye-health-leverage-ai-to-help-family-doctors-screen-and-refer-patients-with-eye-conditions-to-specialists/2479031/AEYE Health and UMass Medical School, in collaboration with UMass Memorial Health Care, are developing a system which enables family doctors to screen patients for various retinal conditions and enable timely referrals to specialists. As part of this effort, AEY
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support
- Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 Drug Candidate in Greater Chinahttps://modernod.com/news/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercialize-tp-03-drug-candidate-in-greater-china/2479026/Tarsus Pharmaceuticals and LianBio announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and M
- Report: Contact Lenses to Advance Well Beyond Refractive Error Correctionhttps://modernod.com/news/report-contact-lenses-to-advance-well-beyond-refractive-error-correction/2479024/A newly-published paper represents one of the most comprehensive reviews of advancements to come in contact lenses, according to the Centre for Ocular Research & Education (CORE).
- Neurolens Announces the Launch of the nMD2 Measurement Devicehttps://modernod.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/Neurolens has announced the launch of the neurolens Measurement Device, Gen 2 (nMD2), an objective and repeatable way to measure binocular vision, or more specifically, eye alignment. Employing over 10,000 data points per patient, the eye tracking system can identify eye misalignment as small as
- EssilorLuxottica Signs Agreement to Acquire Walmanin the UShttps://modernod.com/news/essilorluxottica-signs-agreement-to-acquire-walmanin-the-us/2479016/EssilorLuxottica has entered into an agreement to acquire US-based lab network Walman. Terms of the deal were not disclosed. EssilorLuxottica’s investment in Walman will allow customers to leverage existing and future opportunities to
- Johnson & Johnson Vision Receives Approval in Japan for First Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/Johnson & Johnson Vision announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch: Acuvue Theravision with Ketotifen. The lens contains ketotifen, an H1 histamine receptor antagonis
- Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion by 2026https://modernod.com/news/steady-growth-new-technologies-will-drive-retinal-surgery-device-market-to-1-36-billion-by-2026/2479005/The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report. Retina surgery device sales are driven almost entirely by vitrectomy, a procedure which involves removal of the
- VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Productshttps://modernod.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan. “We’re very excited to work with Wak